文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.

作者信息

Carrasco-Padilla Carlos, Hernaiz-Esteban Alicia, Álvarez-Vallina Luis, Aguilar-Sopeña Oscar, Roda-Navarro Pedro

机构信息

Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid and 12 de Octubre Health Research Institute (imas12), 28040 Madrid, Spain.

Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, 28009 Madrid, Spain.

出版信息

Pharmaceutics. 2022 Dec 30;15(1):132. doi: 10.3390/pharmaceutics15010132.


DOI:10.3390/pharmaceutics15010132
PMID:36678761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9863865/
Abstract

T cell-redirecting strategies have emerged as effective cancer immunotherapy approaches. Bispecific antibodies (bsAbs) are designed to specifically recruit T cells to the tumor microenvironment and induce the assembly of the immunological synapse (IS) between T cells and cancer cells or antigen-presenting cells. The way that the quality of the IS might predict the effectiveness of T cell-redirecting strategies, including those mediated by bsAbs or by chimeric antigen receptors (CAR)-T cells, is currently under discussion. Here we review the organization of the canonical IS assembled during natural antigenic stimulation through the T cell receptor (TCR) and to what extent different bsAbs induce T cell activation, canonical IS organization, and effector function. Then, we discuss how the biochemical parameters of different formats of bsAbs affect the effectivity of generating an antigen-induced canonical IS. Finally, the quality of the IS assembled by bsAbs and monoclonal antibodies or CAR-T cells are compared, and strategies to improve bsAb-mediated T cell-redirecting strategies are discussed.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/9863865/ad9bfe1ca3b9/pharmaceutics-15-00132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/9863865/ad9bfe1ca3b9/pharmaceutics-15-00132-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9fd/9863865/ad9bfe1ca3b9/pharmaceutics-15-00132-g001.jpg

相似文献

[1]
Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.

Pharmaceutics. 2022-12-30

[2]
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.

MAbs. 2018-8-21

[3]
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.

J Transl Med. 2014-12-13

[4]
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.

MAbs. 2023

[5]
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Cell Mol Immunol. 2020-5

[6]
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

J Clin Med. 2021-10-6

[7]
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity.

Pharmaceuticals (Basel). 2021-11-17

[8]
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.

Acta Pharm Sin B. 2024-6

[9]
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.

Curr Opin Oncol. 2023-11-1

[10]
Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.

Antib Ther. 2022-6-9

引用本文的文献

[1]
Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity.

Cancer Immunol Immunother. 2025-6-21

[2]
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.

Clin Pharmacol Ther. 2025-6

[3]
Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies.

Appl Microsc. 2025-1-20

[4]
Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells.

J Immunother Cancer. 2024-12-2

[5]
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies.

Biomol Ther (Seoul). 2024-11-1

[6]
Therapeutic antibodies in oncology: an immunopharmacological overview.

Cancer Immunol Immunother. 2024-10-3

[7]
Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm.

Front Oncol. 2024-8-6

[8]
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells.

Oncoimmunology. 2024

[9]
Changing the location of proteins on the cell surface is a promising strategy for modulating T cell functions.

Immunology. 2024-10

[10]
Nucleolar protein TAAP1/ confers pro-survival signaling in non-small cell lung cancer.

Life Sci Alliance. 2024-4

本文引用的文献

[1]
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).

Int J Mol Sci. 2022-11-17

[2]
Next generations of CAR-T cells - new therapeutic opportunities in hematology?

Front Immunol. 2022

[3]
HER3 in cancer: from the bench to the bedside.

J Exp Clin Cancer Res. 2022-10-21

[4]
Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.

Technol Cancer Res Treat. 2022

[5]
Therapeutic Advances in Immunotherapies for Hematological Malignancies.

Int J Mol Sci. 2022-9-29

[6]
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.

J Adv Pract Oncol. 2022-9

[7]
The Arrival of Gene Therapy for Patients with Hemophilia A.

Int J Mol Sci. 2022-9-6

[8]
A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.

Neurotherapeutics. 2022-9

[9]
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.

J Immunother Cancer. 2022-6

[10]
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Cancer Immunol Res. 2022-4-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索